Physician profile
Scott E Woods
NPI 1093706061
$5,958.84
in general payments reported to CMS, 2019-2025
29 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $965 · 2021: $965 · 2022: $1,065 · 2023: $865 · 2024: $901 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,056 · Education: $4.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,055.52 |
| Education | $4.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,074.93 | 2019-2024 | Jardiance, Synjardy, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $631.13 | 2020-2024 | Airsupra |
| Abbott Laboratories | $419.17 | 2021-2023 | Freestyle Libre 3 |
| Abbvie INC. | $412.93 | 2019-2024 | Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $341.91 | 2023-2025 | |
| Glaxosmithkline, LLC. | $324.03 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Chugai Pharmaceutical Co., LTD. | $300.00 | 2022 | |
| Astellas Pharma US INC | $271.67 | 2024-2025 | Veozah, Xtandi |
| Esperion Therapeutics, INC. | $237.91 | 2020-2021 | |
| Amgen INC. | $215.45 | 2019-2020 | |
| Novo Nordisk INC | $157.53 | 2021-2023 | Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $148.15 | 2022 | |
| Pfizer INC. | $139.50 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.94 | 2020 | |
| Gilead Sciences, INC. | $122.90 | 2024 | Descovy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $121.63 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $120.93 | 2020 | |
| Lucid Diagnostics INC. | $115.13 | 2023 | |
| Janssen Pharmaceuticals, INC | $108.75 | 2020 | |
| Amarin Pharma, INC. | $100.49 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $96.37 | 2019-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Lilly USA, LLC | $94.01 | 2019-2024 | Mounjaro |
| Exact Sciences Corporation | $85.46 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $74.85 | 2022 | |
| Phathom Pharmaceuticals, INC. | $50.83 | 2023-2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $20.12 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.42 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $16.10 | 2023 | Gvoke Hypopen |
| Ultragenyx Pharmaceutical INC. | $14.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Woods listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.